SCHEMBL5650573

SCHEMBL5650573

COC(=O)c1cccc(CN2C(=O)N(Cc3ccc4ccc(C=NN)cc4c3)C(=O)C2(C)c2ccccc2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.42
PTPN1 P18031 5/20 0.39
MAPT P10636 4/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GSK3B P49841 1/20 0.37
OPRD1 P41143 1/20 0.36
POLB P06746 3/20 0.36
LOXL2 Q9Y4K0 1/20 0.35
OPRM1 P35372 1/20 0.35
TAS2R8 Q9NYW2 1/20 0.35
MAPK10 P53779 1/20 0.35
AGTR1 P30556 1/20 0.35
GAA P10253 1/20 0.34
ALDH1A1 P00352 2/20 0.34
LMNA P02545 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
HPGD P15428 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5650040 0.93 PTPN1 (0.45) PTPN1L3MBTL1AGTR1GAAMEN1
SCHEMBL5648162 0.92 KMT2A (0.41) PTPN1MAPTALDH1A1KDM4EKMT2A
SCHEMBL5650848 0.91 CTRB1 (0.39) TRPA1PTPN1OPRD1OPRM1ALDH1A1
SCHEMBL5648228 0.89 PTPN1 (0.40) PTPN1MEN1HPGDKMT2ANPSR1
SCHEMBL5652364 0.88 CTRB1 (0.39) PTPN1MAPTOPRD1OPRM1ALDH1A1
SCHEMBL5647256 0.88 HTT (0.37) TRPA1TAS2R8HTT
Trifluoroacetic Acid SCHEMBL5649098 0.87 CTRB1 (0.36) PTPN1OPRD1OPRM1ALDH1A1LMNA
SCHEMBL5649247 0.87 PTPN1 (0.44) PTPN1MEN1HPGDKMT2A
SCHEMBL5647820 0.86 PTPN1 (0.44) PTPN1MEN1HPGDKMT2A
SCHEMBL5648086 0.86 CTRB1 (0.40) PTPN1MAPTPOLBOPRM1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7199146-B2 Imidazolidinedione analogs useful as anticoagulants and antithrombotics SCHERING AKTIENGESELLSCHAFT (DE) 2007-04-03 US disclosed
US-20060142363-A1 Imidazolidinedione analogs useful as anticoagulants and antithrombotics SCHERING AKTIENGESELLSCHAFT (DE) 2006-06-29 US disclosed
US-7053112-B2 Imidazolidinedione analogs useful as anticoagulants and antithrombotics SCHERING AKTIENGESELLSCHAFT (DE) 2006-05-30 US disclosed
US-20040122073-A1 Imidazolidinedione analogs useful as anticoagulants and antihrombotics SCHERING AKTIENGESELLSCHAFT (DE) 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122073-A1 Imidazolidinedione analogs useful as anticoagulants and antihrombotics SERPINC1, F2, BDKRB1 TRPA1 3373/4885PTPN1 1843/4885MAPT 4868/4885
US-20060142363-A1 Imidazolidinedione analogs useful as anticoagulants and antithrombotics SERPINC1, F2, BDKRB1 TRPA1 1426/4885PTPN1 1936/4885MAPT 4872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.